About Drupal 8
Have you ever felt that your website needs to be more personalized, integrated with cutting-edge technology to offer enhanced user experience?
Valuebound is one of those companies, which specifically help organizations in their path to digital transformation. We enhance digital experience for end users with tailored web applications.
Recent releases
|
Unleashing the Power of AI: A Deep Dive into ChatGPT
Discover the power of OpenAI's language model, ChatGPT, with our informative blog. Learn about its capabilities and potential applications in the field of AI and beyond.
|
Release Plan of Drupal 10 Version: Get Ready to Upgrade
The latest Drupal 10, 10.0.2 has been recently released on 18 January 2023. This release is specifically designed to fix bugs and is now ready to be utilized on live production sites.
|
Celebrating Anoop Singh's Success Story: The ‘Magician’ of Drupal Development at Valuebound
Anoop Singh, a highly skilled Software Development Engineer at Valuebound known for his expertise in Drupal. Sharing his notable achievements and awards in this in-depth interview.
|
Drupal 10: Top 10 Features and Improvements
Explore the top 10 features and improvements of Drupal 10, including enhanced front-end development capabilities, improved security, and a streamlined upgrade process.
CASE STUDY
See all our work
How a Top Indian Pharma Brand Boosted HCP Engagement Using Tech-Led Omnichannel Marketing
India’s renowned pharmaceutical company, known for its strong presence in chronic therapy areas, was facing a growing disconnect with its most important audience: healthcare professionals.
How a Leading Indian Pharma Brand Expanded Reach Across Semi-Urban & Rural Regions
A leading pharmaceutical company in India, well known for its OTC presence and deep connection with mass-market audiences, was preparing to launch a public awareness campaign focused on maternal he
Driving Digital Engagement for a Chronic Care Program with Tech-Led Pharma Marketing
A leading pharmaceutical company in India, known for its chronic care drug portfolio, was preparing to launch a support program aimed at patients diagnosed with congestive heart failure (CHF).
